Horsham, Pa.; August 16, 2022 — Clinical ink, a global life science technology company, will be hosting presentations on the critical importance of incorporating user experience design expertise into clinical study technology at this Fall’s 9^th Annual Mobile Technology in Clinical Trials Conference as well as the 12^th Annual DPHARM (Disruptive Innovations to Modernize Clinical Research) Conference.

First, at the Mobile Technology in Clinical Trials Conference on September 12, 2022,  Joan Severson, Chief Innovation Officer at Clinical ink, will be in conversation with Adama Ibrahim, of Novo Nordisk, Patient Advocate Tina Aswani-Omprakash, MarieElena Cordisco of Nuvance Health, Timothy Joy of Pfizer, and Ash Rishi of COUCH Health on the topic “Solving for the Digital Divide: Building Trust with Mobile Technologies to Increase Patient Participation in Clinical Trials.” The discussion, beginning at 10:30 am ET, will revolve around breaking down barriers to patient access, as well as how to reduce participation anxiety and reimagine trial design to take advantage of digital modalities that can increase patient satisfaction.

The next day, September 13, 2022 during the DPHARM Conference at 11:35 am, Severson will be presenting on the topic of “Patient Science, Usability, and The Future of Clinical Trials.” The talk will cover the importance of integrating user experience design principles into every virtual study—including in-depth research into patient and condition-specific needs, clinical practice, and technology engineering. Severson will demonstrate how Clinical ink embraces these UX concepts via integrating animation, calibration, and feedback directly into mobile study applications—better ensuring inclusivity and access, as well as a more engaging patient experience.

About Clinical ink

Clinical ink is the global life science company that brings data, technology, and patient science together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, neurocognitive testing, and digital biomarkers advancements, drive the industry standard for data precision and usher in a new generation of clinical trials. By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience.  

About DPHARM®   

DPHARM (Disruptive Innovations to Modernize Clinical Research) offers an unparalleled opportunity to hear senior clinical operations executives and innovative thought leaders unveil the latest innovations to modernize clinical trials. 

About Mobile Tech in Clinical Trials  

The Mobile Tech in Clinical Trials Conference helps R&D operation executives support more patients remotely and to understand where these technologies will and won’t work to ensure full patient support while managing invaluable data collection.

The post Clinical ink Advocates for Greater Industry Focus on Patient User Experience appeared first on Clinical ink.

Horsham, Pa.; August 9, 2022 — Clinical ink, a global life science technology company, will be leading the eClincial Forum (eCF) Technology Showcase on Wednesday, September 7 at 10 am ET. Chief Innovation Officer Joan Severson will present on the topic “Tying Passive Data Collection to Active Mobile Measurements.” Severson was asked to present on the topic for a second time, after resounding engagement among eCF members during the June 2022 eClinical Forum Hybrid Workshop. 

The showcase will reveal how Clinical ink’s patient-centric, sensor and wearable-generated, clinically-relevant measurement provides better context for data interpretation. It will also highlight Clinical ink’s advanced technology team’s work in voice data collection and processing, multimodal signal processing, and feature engineering to develop digital biomarkers. 

“We now have access to hardware and sensors capable of extremely sophisticated measurement for the purpose of clinical research,” says Severson. “With the right technological, clinical, and scientific expertise, these can be tapped to transform how clinical research is conducted and how therapies are proven.”

The eCF Technology Showcase solicits speakers via eCF members request, and gives solution providers an opportunity to provide live demonstrations of their products and services.

About Clinical ink  

Clinical ink is the global life science company that brings data, technology, and patient science together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, neurocognitive testing, and digital biomarkers advancements, drive the industry standard for data precision and usher in a new generation of clinical trials. By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience.  

About eClinical Forum    

The eClinical Forum was started in 2000 – a global group run by its members for its members. Independence, openness and public dissemination have been hallmarks of our success. Members from the pharmaceutical, healthcare, regulatory, academic and support sectors participate in open discussion, networking and exchange that provides the practical information, approach and learning experiences required to drive innovation and to maximise the success of eClinical initiatives. 

The group operates in Europe, the Americas and Asia. Membership includes over 50 companies. 

The post Clinical ink Illustrates How to Unlock Sensor and Wearable-Generated Data appeared first on Clinical ink.

Horsham, PA, June 20th, 2022 – David Anderson, PhD, Senior Scientist at Clinical ink, will be presenting insights from our experience designing, deploying, and analyzing the WATCH-PD study in the talk “Disruptive Technologies Simplified: Real World Case Studies.” The session will be held in Basel, Switzerland at the Society for Clinical Data Management (SCDM) 2022 EMEA Leadership Forum & Conference on Thursday, June 23^rd from 3:45-5:00 pm CEST (Brussels) or 9:45-11 am ET (America). 

Anderson, who holds a Ph.D. in Neurological Sciences, has over a decade of experience developing hardware and software capabilities to evaluate mechanisms of visual perception, attention, and working memory. He will speak to how the advanced technology team at Clinical ink integrated data from multiple sensors and assessments, implemented high-dimensional feature engineering pipelines, and evaluated scalable machine learning algorithms to develop digital biomarkers for Parkinson’s in the remotely monitored portion of the WATCH-PD study. 

Learn more about the work Clinical ink has done in Parkinson’s, and the WATCH-PD study.  

About Clinical Ink

Clinical ink is the global life science company that brings data, technology, and patient science together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, neurocognitive testing, and digital biomarkers advancements, drive the industry standard for data precision and usher in a new generation of clinical trials. By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience

About the Society for Clinical Data Management (SCDM) 

Established in 1994, the Society for Clinical Data Management (SCDM) is a non-profit, international organization of over 2,800 members founded to advance the discipline of clinical data management.

SCDM members are charged with promoting quality and excellence in data management and are dedicated to the development, support and advancement of clinical data management professionals. SCDM is organized exclusively for educational purposes and seeks to engage with relevant organizations that can support to advance its mission, to “Connect and inspire professionals managing global health data with global education, certification and advocacy.” Learn more about SCDM.

The post Clinical ink Reveals Disruptive Technologies’ Worth in Clinical Research appeared first on Clinical ink.

Horsham, PA, June 8th, 2022 – Megan Petrylak, Executive Vice President of Customer Delivery at Clinical ink, and Jonathan Andrus with Society for Clinical Data Management will be leading the session “Collection of Quality Endpoint Data in a Decentralized Trial in Complex Indications: The Practical and Logistical Challenges” at DIA 2022 in Chicago on Tuesday, June 21st from 11:00-12:00 pm (CDT). 

When using sophisticated assessments in clinical research, sponsors must capture both structured and unstructured data – on site and remotely. Using disease-specific decentralized clinical trials as examples, Megan and Jonathan will discuss how remotely deployed data capture technology helps to manage both logistically as well as therapeutically complex clinical trials. 

For over 14 years, Petrylak has held various leadership roles within the pharma industry to drive program and operational excellence. At Clinical ink, she leads key organizational initiatives to drive better outcomes for patients. 

Visit with the Clinical ink team in Booth #1701 at DIA 2022 to learn about our clinical trial digital data capture solutions. 

About Clinical Ink

Clinical ink is the global life science company that brings data, technology, and patient science together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, neurocognitive testing, and digital biomarkers advancements, drive the industry standard for data precision and usher in a new generation of clinical trials. By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience.

About DIA

For more than 50 years, DIA has been dedicated to providing a neutral and transparent global forum for the exchange of ideas and collaborations to further scientific and medical innovations. The DIA 2022 Global Annual Meeting brings industry, regulators, academics and patients together to co-create, problem-solve, and discuss global and local challenges facing professionals in the life sciences community.

The post Clinical ink Discusses How Remotely Deployed Data Capture Technology Solves Challenges in Complex, Decentralized Clinical Trials appeared first on Clinical ink.

Horsham, PA, June 7th, 2022 – Joan Severson, Chief Innovation Officer at Clinical ink, will be leading the talk “The Value of Passive Data Collection: Tying Active Assessments to Passive Measurements in Clinical Research” at the eClinical Forum 2022 Hybrid Workshop in New Jersey on Wednesday, June 8^th from 3:50-4:50 pm. She will also facilitate a round-table discussion alongside Kumar Patel of Johnson & Johnson and Akiko Shimamura of Acorn AI on the topic of “Accelerating Clinical Research,” which will cover the value of data coming from EHRs, direct data exchange, real world evidence, and digital health technology.  

Severson, a human-computer interaction expert with over 20 years of experience collaborating with leading pharmaceutical, government, and research institutions, will speak to how her advanced technology and analytics team at Clinical ink unlocks the value of passive and active data collection in clinical research by tying the rich, voluminous patient data compiled by mobile sensors and wearables to clinically-aligned mobile measurements. 

“We now have access to consumer-facing hardware and sensors capable of extremely sophisticated measurement, including of a patient’s life space, mobility, activity levels, speech, and cognition,” says Severson. “Harnessing interdisciplinary collaboration, the right team of technological, clinical, and scientific experts can tap these data to transform how clinical research is conducted and how therapies are proven.” 

About Clinical Ink

Clinical ink is the global life science company that brings data, technology, and patient science together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, neurocognitive testing, and digital biomarkers advancements, drive the industry standard for data precision and usher in a new generation of clinical trials. By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience

About eClinical Forum 

The eClinical Forum was started in 2000 – a global group run by its members for its members. Independence, openness and public dissemination have been hallmarks of our success. Members from the pharmaceutical, healthcare, regulatory, academic and support sectors participate in open discussion, networking and exchange that provides the practical information, approach and learning experiences required to drive innovation and to maximise the success of eClinical initiatives. 

The group operates in Europe, the Americas and Asia. Membership includes over 50 companies. 

The post Clinical ink Reveals Value of Passive Data Collection in Clinical Research appeared first on Clinical ink.

Andrus will participate as a key expert alongside Ann Meeker-O’Connell of IQVIA and Mike Henderson of SAS for the session, “Analytical Tools and Methods to Support Risk-Based Monitoring.” The panelists will explore available analytic approaches, technology, and tools that could support the implementation of RBM.       

“Understanding why RBM approaches have not been widely adopted and what can be done to encourage their use will benefit the entire global pharma and biotech industry,” said Andrus. “I’m honored to have been selected to participate in this discussion.”              

RBM allows sponsors to concentrate their oversight on the most critical, highest risk data elements, procedures, and processes necessary to achieve the objectives of their clinical investigations. This workshop brings together thought leaders from the FDA, EMA, ACRO, BIO, TransCelerate, and more to discuss the challenges, barriers, and enablers that influence the adoption of RBM and opportunities to improve its implementation.

Register to participate in person or via webcast. Contact us for more information on RBM and its pioneering eSource clinical technology platform, eCOA, and ePRO solutions.

About Clinical Ink

Clinical Ink is a global clinical trial technology company that is transforming the clinical trial experience. Founded in 2007, the company’s proven and future-built eSource platform, which includes solutions for EDC replacement, eCOA, ePRO, and more, accelerates time to value while delivering scientific results that matter. With offices in Winston-Salem, NC, and Philadelphia, PA, Clinical Ink is advancing the business model responsible for bringing new treatments to market.

The post Clinical Ink’s Jonathan Andrus Invited to Speak at the Duke-Margolis Center for Health Policy Public Meeting appeared first on Clinical ink.